Concepedia

The novel benzopyran class of selective cyclooxygenase-2 inhibitors. Part III: The three microdose candidates

Jane L. Wang, Karl Aston, David C. Limburg, Cindy Ludwig, Ann E. Hallinan, Francis J. Koszyk, Bruce C. Hamper, David Brown, Matthew J. Graneto, John J. Talley,

Bioorganic & Medicinal Chemistry Letters · 2010 · 36 citations · 5 references

DOIFull text

Open access

Concepts

References

5

Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo.

Joseph P. Portanova, Y Zhang, Graham Anderson et al. · The Journal of Experimental Medicine · 1996 · 420 citations · Full text

, , +17

Inhibition of Cyclooxygenase-2 Rapidly Reverses Inflammatory Hyperalgesia and Prostaglandin E2 Production

Yan Zhang, Alex Shaffer, Joseph P. Portanova et al. · Journal of Pharmacology and Experimental Therapeutics · 1997 · 231 citations

, , +15

Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss and t1/2 be predicted fromin-vivo rat data?

Gary W. Caldwell, John A. Masucci, Zhengyin Yan et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2004 · 145 citations

, , +15

Microdose clinical trial: Quantitative determination of fexofenadine in human plasma using liquid chromatography/electrospray ionization tandem mass spectrometry

Naoe Yamane, Zenzaburou Tozuka, Yuichi Sugiyama et al. · Journal of Chromatography B · 2007 · 75 citations

, , +16

Evaluation of COX-1/COX-2 selectivity and potency of a new class of COX-2 inhibitors

James K. Gierse, Maureen A. Nickols, K. Leahy et al. · European Journal of Pharmacology · 2008 · 34 citations

, , +7